Skip to main content
Premium Trial:

Request an Annual Quote

People in the News

Immunovia: Karin Almqvist Liwendahl, Hans Liljenborg

Immunovia has appointed Karin Almqvist Liwendahl as its CFO. Almqvist Liwendahl was recently the CFO of the medical technology company Dignitana, and has been a financial advisor and CFO at Sprint Bioscience as well as an interim CFO of Kontigo Care. Almqvist Liwendahl also held senior positions at Telia and was the head of investor relations at Ericsson between 1994 and 2000.

Hans Liljenborg, Immunovia's outgoing CFO, will continue with the firm as its finance director.

Grail: Bob Ragusa, Hans Bishop

Illumina has appointed Bob Ragusa as CEO of its subsidiary Grail. He succeeds Hans Bishop, who will serve as advisor to the CEO through the end of 2021 and then step down.

Ragusa is Illumina's chief operations officer, a role in which he helped scale the business globally. He was responsible for the company's clinical lab services, supply chain, quality, life cycle management, information technology, global facilities, and real estate teams.

Prior to Illumina, he was executive VP of engineering and global operations at Accuray, a radiation oncology company, and senior VP of global operations at Applied Biosystems.

Ragusa holds a master's degree in biomedical and electrical engineering from Carnegie Mellon University and an MBA from the University of Connecticut.

Bishop joined Grail's board of directors in 2018 before becoming CEO. He founded Juno Therapeutics in 2013 and was the firm's president and CEO until it was acquired by Celgene. He serves on the boards of Celgene and Agilent Technologies.


Caris Life Sciences: Andreas Tsukada

Andreas Tsukada has joined Caris Life Sciences as senior vice president, president of Japanese operations and head of international. In his new role, Tsukada will oversee operations, market development, regulatory strategy, biopharma partnerships, and strategic initiatives in the region, as well as support Caris' molecular profiling collaboration with the National Cancer Center Japan for the MONSTAR-SCREEN-2 of SCRUM-Japan, the largest cancer genomic screening consortium in the country.

Before joining Caris, Tsukada was general manager and representative director for Japan at Guardant Health. He has over 20 years experience in oncology and diagnostics across the US, Europe, and Asia-Pacific, including working with Thermo Fisher Scientific, where he directed clinical NGS partnerships. Prior to that, Tsukada worked for Merck Biopharma in Japan leading the oncology business unit.

IDbyDNA: Adrian Egli, Tamara Feldblyum, Karl Voelkderding, Christopher Woods, Stephen Young

IDbyDNA has made several appointments to its scientific advisory board. Joining the board are Adrian Egli, head of clinical bacteriology and mycology at University Hospital Basel, Switzerland; Tamara Feldblyum, former branch chief in the Division of Microbiology Devices at the US Food and Drug Administration's Center for Devices and Radiological Health Office of In Vitro Diagnostics and Radiological Health; Karl Voelkerding, an expert in genomics and a member of the College of American Pathologists and the Association for Molecular Pathology; Christopher Woods, executive director of the Hubert-Yeargan Center for Global Health and professor of medicine and pathology at Duke University; and Stephen Young, director of research and clinical trials at TriCore Reference Laboratory.

Foundation Medicine: Dymeka Harrison

Foundation Medicine has appointed Dymeka Harrison as chief commercial officer, where she will develop and execute global clinical commercial strategy and strengthen customer relationships, as well as establish new partnerships. She most recently served as VP of global strategic marketing at Abbott, overseeing global marketing efforts for the firm's rapid diagnostics division. Harrison also worked at Qiagen as VP of sales for its QuantiFeron and AmniSure businesses and was a national sales manager in the clinical division at BioMérieux. She has also served as a sales director at Thermo Fisher Scientific.

Oncocyte: Gisela Paulsen

Oncocyte has appointed Gisela Paulsen as its chief operating officer. She joins the company having most recently served as general manager of Genomic Health following its acquisition by Exact Sciences. She has also held senior roles at Roche/Genentech and Health Learning Systems, the founding medical education unit of Ogilvy. Paulsen is currently an entrepreneur in residence at DigitalDX Ventures and has served on the board directors of the healthcare businesswomen association, CuriOdyssey, and the Genentech Foundation.

Delfi Diagnostics: Doug Schenkel

Delfi Diagnostics has appointed Doug Schenkel its CFO. He joins Delfi from investment bank Cowen where he was most recently managing director and senior analyst, leading the life science and diagnostic tools franchise. In that role, Schenkel covered more than 50 companies for more than 20 years. Cowen Chair and CEO Jeffrey Solomon said in a statement that Schenkel will remain as a senior advisor to the bank as he transitions to Delfi.

Renalytix: Jed Fulk

Renalytix has appointed Jed Fulk as its vice president of sales, government accounts. Fulk is developing and leading a team expected to grow to 42 regional sales managers and account executives during 2022 to support the rollout of its KidneyIntelX test to the VA Health System. The test helps physicians identify diabetic kidney disease patients at high and low risk for rapid progression and kidney failure.

Saga Diagnostics: Peter Collins

Saga Diagnostics, a cancer liquid biopsy and genomic testing company based in Sweden, has appointed Peter Collins as its CEO. Previously, Collins was the chief business officer at Inivata; vice president of biopharma business development at Guardant Health; and chief business officer at Yourgene. For five years, he was the vice president and head of diagnostics at GSK. 

Specific Diagnostics: Scott Mendel

Specific Diagnostics has appointed Scott Mendel to its board of advisors. Mendel had been the CEO of GenMark Diagnostics since 2020 and managed the process that led to its purchase by Roche Diagnostics this year for $1.8 billion. Previously, he had been GenMark's chief operating officer and CFO. Prior to joining GenMark, Mendel held CFO positions at the Active Network and GE Healthcare.